Monoclonal antibody · Antagonist of vascular endothelial growth factor A (VEGF-A) (VEGFA) · developed by Novartis Pharms
Brolucizumab is a human antibody that binds the three major isoforms of VEGF-A, preventing VEGF-A from interacting with VEGFR-1 and VEGFR-2. By inhibiting VEGF-A it suppresses endothelial cell proliferation, neovascularization and vascular permeability. It is studied in neovascular age-related macular degeneration and diabetic macular edema.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Oct 26, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04543331 | N/A | Neovascular Age-related Macular Degeneration (nAMD) | Completed | NVS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Diabetic Macular Edema (DME)Neovascular Age-related Macular Degeneration (nAMD)
Updated Nov 22, 2026. Something wrong or missing? Report it on the NVS page.
See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NVS catalysts and pipeline →